AI Article Synopsis

  • A 79-year-old woman with a history of lymphoma experienced severe anemia and was diagnosed with pure red cell aplasia (PRCA) and autoimmune hemolytic anemia.
  • Despite initial treatment with rituximab showing limited effectiveness, further treatment with cyclosporine resulted in a swift recovery of her red blood cell production.
  • This case highlights the successful use of cyclosporine for treating anti-erythropoietin receptor antibody-associated PRCA in a lymphoma patient.

Article Abstract

A 79-year-old female diagnosed with T cell/histiocyte-rich large B cell lymphoma in complete remission after six cycles of rituximab-combined chemotherapy developed severe anemia, reticulocytopenia, and bone marrow erythroid hypoplasia. She was diagnosed with pure red cell aplasia (PRCA) accompanied by Coombs-negative autoimmune hemolytic anemia evidenced by a lack of glycophorin-A-positive cells in the bone marrow, haptoglobin under the detection level, and a high titer of RBC-bound IgG. Anti-erythropoietin receptor (EPOR) antibody was detected in the serum, and oligoclonal α/β and γ/δ T cells were also detected in her peripheral blood by Southern blotting analysis. Parvovirus B19 DNA was not detected by PCR. Although the treatment with rituximab had limited efficacy (specifically, only for hemolysis), subsequent cyclosporine therapy led to prompt recovery of erythropoiesis with the disappearance of anti-EPOR antibody and oligoclonal T cells. This is the first case report of anti-EPOR antibody-associated PRCA in a patient with malignant lymphoma treated successfully with cyclosporine.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-014-1652-5DOI Listing

Publication Analysis

Top Keywords

anti-erythropoietin receptor
8
pure red
8
red cell
8
cell aplasia
8
accompanied coombs-negative
8
coombs-negative autoimmune
8
autoimmune hemolytic
8
hemolytic anemia
8
cell/histiocyte-rich large
8
large cell
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!